Moving Forward with Confidence
to reach our mission and create value
SonALAsense’s Sonodynamic Therapy (SDT) is a noninvasive technology with the potential to be a safe and effective treatment for cancer. We have positive proof-of-concept results in a first-in-man Phase 0/1 clinical trial in recurrent high grade gliomas and in a first-in-child Phase 1/2 clinical trial in diffuse intrinsic pontine glioma (DIPG).
SonALAsense has raised over $20 million from accredited biotech investors, many of whom have personal experience with the tragedy of cancer. We have recently received an ARPA-H award of up to $46MM for the development of SONALA-001 SDT in blood cancers.
Please contact info@sonalasense.com if you are interested in joining our investor syndicate.
SonALAsense would like to extend our sincere thanks to those individuals and groups that have invested in our mission and vision. We think of them as part of our SonALAsense family. We look forward to a future of building better health outcomes and enhancing the lives of people for the patient communities we serve. On behalf of our leadership team and all SonALAsense employees, we thank you for your trust and ongoing support.
.png)
.png)
.jpg)
.png)
